Protagonist Rusfertide Phase 2 at the EHA2024 Congress Showing Durable Hematocrit Control

 

• Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera
• Patients receiving rusfertide in the open-label extension of the REVIVE study are eligible to roll over to the THRIVE study for an additional 2 years of treatment

https://www.biospace.com/article/releases/protagonist-reports-updated-long-term-results-from-rusfertide-phase-2-revive-study-at-the-eha2024-congress-showing-durable-hematocrit-control/